Lyell Immunopharma (United States)

Recent papers from Lyell Immunopharma (United States)

1. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trialNature Medicine · 2020
2. Statistical analysis plan considerations for autologous cell and cell-based gene therapy clinical trialsJournal of Biopharmaceutical Statistics · 2026
3. Overview of dose-finding designs and trials in cell and gene therapiesJournal of Biopharmaceutical Statistics · 2026
4. Juçara Berry ( Euterpe edulis Martius ) As a Natural Source of Antioxidants: Modulation of Biochemical and Oxidative Stress Markers in RatsACS Nutrition Science · 2026
5. Real-world data and evidence in the development of cell and gene therapiesJournal of Biopharmaceutical Statistics · 2026
6. Polypharmacology is an enduring and nearly universal property of kinase inhibitors2026
7. Advancing cell and gene therapy: Application of AI/ML in clinical development and patient managementJournal of Biopharmaceutical Statistics · 2026
8. Modulating AP-1 enables CAR T cells to establish an intratumoral stemlike reservoir and overcomes resistance to PD-1 blockadeScience Immunology · 2026
9. Applications of correlative analysis for chemistry, manufacturing and controls in cell and gene therapy.2026
10. Rondecabtagene autoleucel, an autologous, dual-targeting CD19/CD20 CAR T-cell candidate manufactured from CD62L+ enriched T cells, achieves durable responses in patients with large B-cell lymphomaBlood · 2025
11. Estimands for long-term follow-up trials in gene therapy productsJournal of Biopharmaceutical Statistics · 2025
12. Modulating AP-1 enables CAR-T cells to establish an intratumoral PD-1 ⁺ Tcf1 ⁺ stem-like reservoir and overcomes resistance to PD-1 axis blockade2025
13. Engineering potent chimeric antigen receptor T cells by programming signaling during T-cell activationScientific Reports · 2024
14. Abstract 6593: Rejuvenation of tumor-infiltrating lymphocytes (TIL): A novel strategy to revitalize TIL antitumor function for cell therapyCancer Research · 2024
15. Abstract 4067: Development of tumor-restricted IL-12 with antigen-dependent expression and localized IL-12 activityCancer Research · 2024
16. Abstract 49: LYL119, an investigational ROR1-targeted CAR T-cell product incorporating four novel reprogramming technologies designed for effective cell therapy for solid tumorsCancer Research · 2024
17. Accelerating the development of genetically engineered cellular therapies: a framework for extrapolating data across related productsCytotherapy · 2024
18. Identification of pan-cancer/testis genes and validation of therapeutic targeting in triple-negative breast cancer: Lin28a-based and Siglece-based vaccination induces antitumor immunity and inhibits metastasisJournal for ImmunoTherapy of Cancer · 2023
19. 379 Epi-RTM P2 protocol produces a scalable polyclonal TIL product with a greater expansion success rate across hot and cold tumors in shorter culture timeRegular and Young Investigator Award Abstracts · 2023
20. Adaptively leveraging external data with robust meta‐analytical‐predictive prior using empirical BayesPharmaceutical Statistics · 2023